James C. Mullen, Patheon's Chief Executive Officer said, "We are very happy to have reached an agreement with Bellwyck for this business. While we don't expect the terms of the transaction to have a material impact on our on-going results, this transaction is part of our continued focus on our core competencies of solid-dose and parenteral development and manufacturing. One of Bellwyck's core competencies is clinical packaging. We are confident that both the customers and our employees, about 20 of whom have joined Bellwyck, are in good hands."
Jeff Sziklai, Bellwyk's Co-CEO, said, "We look forward to an ongoing partnership with Patheon as we work together to ensure that Bellwyck continues to provide superior clinical packaging and distribution services to Patheon's current and future customers. We anticipate a seamless transition for customers and employees."
Patheon's secondary clinical packaging and clinical distribution services business is globally managed from its Burlington, Ontario, Canada facility, and includes an operating presence in Cincinnati, Ohio. Terms of the sale have not been disclosed.
